Arrowhead Pharmaceuticals

YTD

ALL

Trade Arrowhead Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ARWR

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.

CEO

Christopher Richard Anzalone

CEOChristopher Richard Anzalone

Employees

711

Employees711

Headquarters

Pasadena, California

HeadquartersPasadena, California

Founded

1989

Founded1989

Employees

711

Employees711

ARWR Key Statistics

Market cap

14.09B

Market cap14.09B

Price-Earnings ratio

-39.84

Price-Earnings ratio-39.84

Dividend yield

—

Dividend yield—

Average volume

2.77M

Average volume2.77M

High today

$88.00

High today$88.00

Low today

$85.06

Low today$85.06

Open price

$86.84

Open price$86.84

Volume

1.81M

Volume1.81M

52 Week high

$95.49

52 Week high$95.49

52 Week low

$15.01

52 Week low$15.01

Stock Snapshot

The current Arrowhead Pharmaceuticals(ARWR) stock price is $85.60, with a market capitalization of 14.09B. The stock trades at a price-to-earnings (P/E) ratio of -39.84.

During the trading session on 2026-07-25, Arrowhead Pharmaceuticals(ARWR) shares reached a daily high of $88.00 and a low of $85.06. At a current price of $85.60, the stock is +0.6% higher than the low and still -2.7% under the high.

Trading activity shows a volume of 1.81M, compared to an average daily volume of 2.77M.

The stock's 52-week range extends from a low of $15.01 to a high of $95.49.

ARWR News

Simply Wall St 2d

Arrowhead Pharmaceuticals Is Up 23.5% After Strong Plozasiran Phase 3 Data in Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals recently reported topline results from its global Phase 3 SHASTA-3 and SHASTA-4 trials, showing that plozasiran achieved large triglyc...

Benzinga 3d

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Benzinga

...

TipRanks 3d

Arrowhead Pharmaceuticals Stock Soars on Strong Phase 3 Trial Results

Arrowhead Pharmaceuticals (ARWR) stock was on the rise Wednesday after a clinical-trial update from the biopharmaceutical company. The company reported strong P...

Analyst ratings

93%

of 14 ratings

Buy

92.9%

Hold

7.1%

Sell

More ARWR News

TipRanks 3d

Arrowhead’s ARO-033 First-in-Human Trial: What Early Safety Progress Means for ARWR Investors

Arrowhead Pharmaceuticals, Inc. (ARWR) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smart...

Seeking Alpha 3d

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

Arrowhead Pharmaceuticals (ARWR) on Wednesday announced a late-stage trial win for its lipid-lowering agent plozasiran in patients with severe hypertriglyceride...

Simply Wall St 7d

Is Arrowhead Pharmaceuticals Undervalued Or Is Its Pipeline Promise Already Priced In?

Arrowhead Pharmaceuticals (ARWR) has drawn investor attention after recent share price moves, with the stock up about 4.1% over the past day but down roughly 8....

People also own

Based on the portfolios of people who own ARWR. This list is generated using Robinhood data, and it’s not a recommendation.

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.